Volume 1, Number 2 (4-2017)                   MCI 2017, 1(2): 1-2 | Back to browse issues page



DOI: 10.21859/mci-01025

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Geijtenbeek T B H. Dendritic Cell Immunotherapy, the Next Step in Cancer Treatment. MCI. 2017; 1 (2) :1-2
URL: http://mcijournal.com/article-1-56-en.html

Abstract:   (894 Views)

Cancer immunotherapy has gained a lot of interest over the past few years due to the success of immune checkpoint inhibitors in treating cancer (1, 2). Immune checkpoint inhibitors, such as monoclonal antibodies against cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) and programmed death 1 (PD-1), have been shown to increase survival of patients with advanced cancers (1, 2). These inhibitors rely on preventing immunosuppression and enhancing anti-tumor responses. Under healthy conditions, over-activation of T cell immunity is controlled by immune checkpoints, which are molecules that suppress T cell function and thereby prevent uncontrolled T cell activation and autoimmunity.
....

Full-Text [PDF 69 kb]   (573 Downloads)    
Type of Study: Editorial | Subject: immunotherapy and regenerative medicine
Received: 2016/09/24 | Accepted: 2016/12/3 | ePublished: 2017/04/1

Add your comments about this article : Your username or email:
Write the security code in the box

Send email to the article author


© 2015 All Rights Reserved | Multidisciplinary Cancer Investigation

Designed & Developed by : Yektaweb